




# IDSA's 2026 Vaccine Guideline Updates

SAVRR Council

Sept. 8, 2026



# About IDSA Guidelines

**IDSA practice guidelines** are developed by panels of experts to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances.

Based on policies & principles:

- a. **CMSS** principles for Conflicts of Interest
- b. The **IOM** standards for Systematic Reviews & Clinical Practice Guidelines
- c. **GRADE** framework and other consensus-based methodologies



## COVID-19 Subgroup



**Katherine Belden, MD**  
**(Subgroup Lead)**  
Thomas Jefferson University



**Kristina Bajema, MD, MSc**  
Oregon Health & Science University



**Dean Blumberg, MD**  
University of California Davis



**Anoma Nellore, MD**  
NYU Langone Health

## Guideline Panel Chair



**Lindsey Baden, MD**  
Brigham and Women's Hospital; Harvard Medical School

## Influenza Subgroup



**Paul Goepfert, MD**  
**(Subgroup Lead)**  
University of Alabama at Birmingham



**Morgan Katz, MD, MHS**  
The Johns Hopkins University



**Daniel Kaul, MD**  
University of Michigan Medical School



**Tanvi Sharma, MD, MPH**  
Boston Children's Hospital; Harvard Medical School



## RSV Subgroup



**Chen Sabrina Tan, MD**  
(Subgroup Lead)  
University of Iowa



**Shweta Anjan, MD**  
University of Miami



**Ella Ariza Heredia, MD**  
MD Anderson Cancer  
Center.



**Francisco Magana, MD**  
The Ohio State University



**Timothy Minniear, MD**  
University of Tennessee;  
Le Bonheur Children's  
Hospital

## IDSA Staff & Consultants




**Jon Heald**  
Senior Director,  
Clinical Policy



**Genet Demisashi**  
Director of Operations



**Elizabeth York**  
Guidelines  
Specialist &  
Project Lead



**Loretta Dzanya**  
Program Coordinator



**Senam Attipoe**  
Program  
Assistant  
(Consultant)




**Sheena Patel**  
Methodologist  
(Consultant)




**Yngve Falck-Ytter, MD**  
Lead Methodologist  
(Consultant)

# Conducting the Systematic Review




# Developing the Recommendation(s)





# 2026-27 Guideline Update

*Timeline*





# COVID-19 Vaccination

## Recommendation:

In adults and children with compromised immunity\*, the IDSA guideline panel recommends administering age-appropriate 2026-2027 COVID-19 vaccinations (strong recommendation, moderate certainty of evidence).

*\*see risk and timing table*

## Remarks:

- An FDA-approved 2026-2027 COVID vaccine should be given as soon as possible and within the framework in Table 1.
- Approved 2026-2027 COVID vaccines include mRNA and recombinant protein subunit products.
- Patients may receive age-appropriate COVID-19, influenza, and RSV vaccines together.
- For never vaccinated and incompletely vaccinated patients refer to published guidelines [2].
- Household members and close contacts of immunocompromised patients should be up to date with COVID-19 vaccination.
- A second booster dose of 2026-2027 COVID-19 vaccination may extend protection.



# Influenza Vaccination

## Recommendation:

In adults and children with compromised immunity\*, the IDSA guideline panel recommends administering age-appropriate 2026-2027 Influenza vaccinations (strong recommendation, moderate certainty of evidence).

*\*see risk and timing table*

## Remarks:

- Vaccination must be repeated on an annual basis to provide optimal protection.
- Approved influenza vaccines include egg-based inactivated influenza vaccines (IIV), cell culture-based inactivated influenza vaccines (ccIIV), recombinant influenza vaccines (RIV), and mRNA\*\* influenza vaccines.
- High-dose or adjuvanted influenza vaccines provide more robust immune response, which may be of particular importance in immunocompromised patients.
- Household members and close contacts of immunocompromised patients should be up to date with influenza vaccination.
- Live-attenuated influenza vaccines are contraindicated for immunocompromised hosts and should be avoided in close contacts of severely immunosuppressed individuals (e.g., recent hematopoietic cell transplantation [HCT] recipients, patients with graft-versus-host disease [GVHD], patients with severe combined immunodeficiency).
- Patients may receive age-appropriate COVID-19, influenza, and RSV vaccines together.

*\*\*Approved on August 5, 2026. Data on immunocompromised patients are limited*



# RSV Vaccination

## Recommendation:

In adults and adolescents with compromised immunity\*, the IDSA guideline panel recommends administering age-appropriate RSV vaccinations (strong recommendation, moderate certainty of evidence).

*\*see risk and timing table*

## Remarks:

- FDA approved RSV vaccines for adults include RSVPreF3, RSVPreF, and mRNA-1345.
- While there is limited data for immunocompromised adolescents, the panel believes the benefits of offering the vaccine outweigh the risks. Administration should be guided by shared decision making.
- Solid organ transplant candidates, especially lung transplant, should ideally be vaccinated pre-transplant.
- Additional doses of the RSV vaccine to be guided on case-by-case basis (or shared decision making with treating physician).
- Household members and close contacts of immunocompromised patients should be up to date with RSV vaccination as eligible.
- Patients may receive age-appropriate COVID-19, influenza, and RSV vaccines together.

Thank you!

